Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vor Biopharma Inc (NQ: VOR )

4.700 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 100
Open 4.700
Bid (Size) 4.500 (1)
Ask (Size) 5.370 (2)
Prev. Close 4.700
Today's Range 4.700 - 4.700
52wk Range 3.480 - 7.570
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2023
 
Via Benzinga
8 Analysts Have This to Say About Vor Biopharma
 
Via Benzinga

Performance

YTD
-30.47%
-30.47%
1 Month
+9.56%
+9.56%
3 Month
-14.70%
-14.70%
6 Month
+2.17%
+2.17%
1 Year
+11.64%
+11.64%

More News

Read More
Vor Biopharma: Q1 Earnings Insights
Via Benzinga
Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Where Vor Biopharma Stands With Analysts
Via Benzinga
Truist Securities Maintains Buy Rating for Vor Biopharma: Here's What You Need To Know
Via Benzinga
Dow Rises 50 Points; Oxford Industries Shares Plunge
Via Benzinga
Why Scholastic Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Vor Biopharma's Leukemia Cell Exhibits Favorable Engraftment Five Months Post-Transplant
Via Benzinga
First AML Patient Transplanted with Vor Bio’s Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level
From Vor Biopharma
Via GlobeNewswire
Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings
From Vor Biopharma
Via GlobeNewswire
Vor Bio to Present at B. Riley Securities’ 3rd Annual Oncology Conference
From Vor Biopharma
Via GlobeNewswire
Analyzing Vor Biopharma's Short Interest
Via Benzinga
Dow Edges Higher; Prometheus Biosciences Shares Jump
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Nasdaq Drops 75 Points; Crude Oil Down 2%
Via Benzinga
Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million
From Vor Biopharma
Via GlobeNewswire
First AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated Mylotarg™
From Vor Biopharma
Via GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update
From Vor Biopharma
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.